The Global Health Body Raises Alert Over Severe Shortage of Weight-Loss Medications
Under 10% of people that would benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it releases its first guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our latest guidance affirms that excess weight is a lifelong illness that can be treated with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major hurdles to widespread availability to the injections that can assist patients in reducing substantial body mass, explains the body.
Weight-Loss Drug Shortage
Even under the present most favorable case, the production of such drugs could only cover about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice calls on countries and companies to widen access, by strategies such as patent sharing.
A patent on the active ingredient – the core component of a leading brand – is set to lapse in several nations in 2026.
How Obesity Injections Operate
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so people consume fewer calories.
Patients typically start to lose weight within a few weeks of starting on the regular doses.
Evidence suggests users may see weight return within a year of stopping the drug, when their typical hunger come back.
To be above a healthy weight raises your likelihood for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects people in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
